Biopharma News : Biopharma and Pharma news from all around the world :
- Milliman Retiree Health Cost Index: A 65-year-old couple needs $395,000 in savings for healthcare in retirement
- Biogennix Launches Agilon Surgical Matrix
- United States Tuberculosis Drugs Market Prospects, Trends Analysis, Size and Forecasts up to 2032 – ResearchAndMarkets.com
- OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer
- Exai Bio Appoints Dave Daly as Chief Executive Officer
- Pharmaceutical Industry Chief Kåre Schultz Joins Hims & Hers Board
- Lario Therapeutics Awarded $6M Grant From The Michael J. Fox Foundation for Parkinson’s Research
- Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
- AHF Press Conference: Advocates Demand Gilead to Put Lives Before Profits at AIDS 2024
- TME Pharma Announces Strategic Plan to Externalize and Monetize Second Clinical Stage Asset NOX-E36
- Rusan Pharma’s API Plant in Ankleshwar Receives (India) USFDA GMP Approval
- Almirall’s H1 2024 Results: Almirall Delivers Strong Performance in the First Half of 2024, Achieving Net Sales Growth of 6.7% Driven by Its European Dermatology Business and Accelerating Biologics Sales
- Apollo Therapeutics and the University of Oxford Enter Into Drug Discovery and Development Collaboration
- StatLab Expands Operational Footprint in Europe
- AiCuris Announces Milestone Achievements Further Validating its Pipeline of Anti-viral Solutions for Immunocompromised Patients
- TME Pharma Announces Oral Presentation of NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma at ESMO Congress 2024
- Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity
- Kerecis Silicone Fish-Skin Combination for Wound Healing Receives Approval from Palmetto Insurance Group
- ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
- Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024
- Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024
- Eighth Annual Navitus Drug Trend Report Reveals How Plan Sponsors Save on Prescription Drugs Amid Rising Costs and Inflation
- Diakonos Oncology Receives FDA Fast Track Designation for Pancreatic Cancer Dendritic Cell Vaccine; Names Daniel D. Von Hoff, M.D. to Scientific Advisory Board
- Mogrify Appoints Dr Jonathan Appleby as Chief Scientific Officer
- Poxel Provides an Update on Its Financial Position for the Second Quarter and First Half of 2024 and Announces the Rescheduling of Its Annual General Meeting
- Sensorion Announces New Positive Secondary Efficacy Endpoints Data From SENS-401 Phase 2a Clinical Trial For The Preservation Of Residual Hearing Loss
- Sensient Announces Conference Call
- Scenic Biotech Appoints Industry Veteran Ben Machielse to Board of Directors
- Bioptimus Launches H-optimus-0, the World’s Largest Open-Source AI Foundation Model for Pathology
- GenSight Biologics Launches Newsletter for Retail Investors
News about Biotech, Pharma, Biopharma, Medical Devices, Diagnostics, Digital Health
- Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®
- Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA
- Vitruvia Medical AG: Half yearly results as per June 30th, 2024
- Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
- Drägerwerk AG & Co. KGaA: Dräger on track to meet annual forecast after a solid first half-year
- Curatis Holding AG: Initiation of Coverage and Publication of Equity Research Report by valuationLAB
- Lonza Nominates Juan Andres and Eric Drapé as Independent Board Members
- Lonza Group H1 2024 Performance Well On Track to Deliver Full-Year Outlook: Sales Up 1.8% CER and 29.2% CORE EBITDA Margin
- Medacta Group SA: Medacta Group SA revenues grew 14.3% at constant currency in 1H 2024
- Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec (news with additional features)
- DEFENCE THERAPEUTICS GRANTED CNRI-H FROM THE CANADIAN NUCLEAR LABORATORIES TO ACCELERATE THE DEVELOPMENT OF ITS RADIO-IMMUNO-CONJUGATES PROGRAM
- Galenica increases shareholding in Redcare Pharmacy to 10%
- Secarna Pharmaceuticals publishes new data in Nucleic Acid Therapeutics showcasing strategies to detect and prevent immunostimulatory potential of LNA-modified ASOs
- Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia
- Spexis expects that audit of its 2023 financials will not be completed by 31 July 2024, provides status update relating to the Company’s moratorium and changes to its Executive Committee.
- Half-year results 2024 of SartoriusStedimBiotech
- CHEPLAPHARM reorganises Management Team
- DOUGLAS Group raises sales forecast for the financial year 2023/24 and sells online pharmacy Disapo
- Eckert & Ziegler Again Increases Sales and Earnings Compared to Previous Year. Profit Forecast Raised for 2024.
- Driving subcutaneous self-injection of large volume doses: SCHOTT Pharma launches large format ready-to-use cartridges for on-body devices
- Abivax Provides Operational and Key Program Update
- Sales growth Q2/2024 +14 % and H1/2024 +10 % compared to previous year; positive development in all operating areas
- Affluent Medical announces the availability of a prospectus for the admission to trading of 6,190,831 shares issued as part of a capital increase without preferential subscription rights in favour of
- Nyxoah Appoints Scott Holstine as Chief Commercial Officer
- Evolva Holding SA: Approval of temporary exemption from certain conditions for maintaining listing pursuant to art. 7 Listing Rules; IFRS financial statements for 2023 and half-year 2024 to be publish
- MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
- Drägerwerk AG & Co. KGaA: Preliminary figures H1 2024: Earnings above prior year
- Ad hoc: Merger Squeeze-out Cash Compensation Determined at EUR 68.00
- Affluent Medical signs agreements for mitral valve technologies with EUR 15M upfront payment
- CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
- TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Second Quarter 2024 Financial Results on August 1, 2024
- Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
- vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
- NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
- EssilorLuxottica: Publication of the 2024 Interim Financial Report
- eLabNext and ABI-LAB Announce Strategic Partnership to Foster Innovation in Life Sciences
- BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo
- Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab
- Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
- Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
- Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
- ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer’s Trial
- OneMedNet Announces $4.6 Million Private Placement
- ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
- Bavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine
- California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
- California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
- OnKure Announces the Appointment of Dylan Hartley as Chief Scientific Officer
- BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
- 23andMe to Report Q1 FY2025 Financial Results
- Travere Therapeutics to Report Second Quarter 2024 Financial Results
- Travere Therapeutics to Report Second Quarter 2024 Financial Results
- 23andMe to Report Q1 FY2025 Financial Results
- FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
- FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
- Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
- Cronos Group Inc. to Hold 2024 Second Quarter Earnings Conference Call on August 8, 2024
- Oxurion Share Consolidation
- EssilorLuxottica: Q2/H1 2024 Results – Sound revenue growth, margins expanding, two acquisitions in line with strategy
- GUERBET : H1 2024 revenue.
Sources for this page of Biopharma News : biopharma-reporter.com and worldpharmanews and pharmatimes.com and drugs.com and fiercepharma.com and scripintelligence.com and PR Newswire and Business Wire. Please visit all this very interesting websites for more info.
Biopharma News – Pharma News